



09-03-04

IFW

PATENT
678503-2005.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Korokhov et al.
Serial No. : 10/624,317
Filed : July 22, 2003
For : TARGETED ADENOVIRAL VECTOR DISPLAYING
IMMUNOGLOBULIN-BINDING DOMAIN AND USES
THEREOF
Group Art Unit : 1645

745 Fifth Avenue
New York, NY 10151

EXPRESS MAIL

Mailing Label Number: EV 206805965 US
Date of Deposit: September 2, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: **Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Adam Ahmed
(Typed or printed name of person mailing paper or fee)

A. Ahmed
(Signature of person mailing paper or fee)

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97(b)(3) AND 1.98

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The Examiner's attention is respectfully drawn to the enclosed documents listed on the accompanying PTO Form 1449.


Pursuant to 37 CFR §1.97(b)(3), Applicants request the Examiner to consider this Information Disclosure Statement, and to make of record the documents cited on the accompanying PTO form 1449 and that a copy of Form PTO-1449 be initialed by the Examiner and returned to the undersigned.

The filing of this Information Disclosure Statement is not an admission that the documents identified herein constitute prior art to the present application.

It is believed that no fees are required by the instant submission as it is prior to receipt of the first Office Action on the merits. However, if any fees are required, or if any overpayment has been made, please charge Deposit Acct. No. 50-0320.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP
Attorneys for Applicants



Thomas J. Kowalski

Reg. No. 32,147


Deborah L. Lu

Reg. No. 50,940

Tel. No. (212) 588-0800

Fax No. (212) 588-0500

Encs. PTO Form 1449
References (24)

Based on Form PTO/AIA 449
(3/90)

ATTY. DOCKET NO.

678503-2005.1

SERIAL NO.

10/624,317

APPLICANT

Korokhov et al.

FILING DATE

July 22, 2003

GROUP

1645

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AC							
	AD							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AE		Altman et al., Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94-6 (1996).					
	AF		Belousova et al., Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol. 76:8621-31 (2002).					
	AG		Chartier et al., Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol. 70:4805-10 (1996).					
	AH		Dmitriev et al., Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol. 74:6875-84 (2000).					
	AI		Graham and Prevec, Methods for construction of adenovirus vectors. Mol. Biotechnol. 3:207-20 (1995).					
	AJ		Heiser et al., Autologous dendritic cells transfected with prostatespecific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin. Invest. 109:409-17 (2002).					
	AK		Hong and Engler, Domains required for assembly of adenovirus type 2 fiber trimers. J Virol. 70:7071-8 (1996).					
	AL		Krasnykh et al., Genetic targeting of adenovirus vector via replacement of the fiber protein with the phage T4 fibrin. J. Virol. 4176-4183 (2001).					
	AM		Krasnykh et al., Genetic targeting of adenoviral vectors. Mol. Ther. 1:391-405 (2000).					
	AN		Krasnykh et al., Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol. 72:1844-52 (1998).					
	AO		Krasnykh et al., Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol. 70:6839-46 (1996).					
	AP		Krasnykh and Douglas, Targeted adenoviral vectors I: Transductional targeting. In Curiel and Douglas ed., Adenoviral Vectors for Gene Therapy. Academic Press, San Diego (2002).					
	AQ		Lo et al., High level expression and secretion of Fc-X fusion proteins in mammalian cells. Protein Eng. 11:495-500 (1998).					
	AR		Lodge et al., Expression and purification of prostate-specific membrane antigen in the baculovirus expression system and recognition by prostate-specific membrane antigen-specific T cells. J Immunother. 22:346-55 (1999).					
	AS		Meidenbauer et al., Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 43:88-100 (2000).					
	AT		Pereboev et al., Coxsackievirus-adenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic cells. Gene Ther. 9:1189-93 (2002).					

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Based on Form PTO-1449 (3/90) LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				ATTY. DOCKET NO. 678503-2005.1		SERIAL NO. 10/624,317	
				APPLICANT Korokhov et al.			
				FILING DATE July 22, 2003		GROUP 1645	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AU						
	AV						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	AW						
	AX						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AY		Salgaller et al., Dendritic cell-based immunotherapy of prostate cancer. Crit. Rev. Immunol. 18:109-19 (1998).				
	AZ		Tasch et al., A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit. Rev. Immunol. 21:249-61 (2001).				
	BA		Tillman et al., Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res. 60:5456-63 (2000).				
	BB		Tillman et al., Maturation of dendritic cells accompanies high efficiency gene transfer by a CD40-targeted adenoviral vector. 5 J Immunol. 162:6378-83 (1999).				
	BC		Tjoa and Murphy, Progress in active specific immunotherapy of prostate cancer. Semin. Surg. Oncol. 18:80-7 (2000).				
	BD		Von Seggern et al., Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein-Barr virus-transformed B cells. J Virol. 74:354 (1999)				
	BE		Zou et al., Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by beta-chemokines rather than IL-12. J Immunol. 165:4388 (2000)				
	BF		Zou et al., Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med. 7:1339 (2001)				
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						
	BM						
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							